cannabidiol cream (medical grade cannabis ointment) / OWC Pharma - LARVOL DELTA

Ixekizumab shows strong efficacy, safety through 108 weeks in pediatric psoriasis (Healio) - "'About 1% of children and adolescents worldwide are affected by plaque psoriasis,' Amy S. Paller, MD...wrote. In the multicenter, randomized clinical trial, Paller...assessed the long-term efficacy and safety of ixekizumab (Taltz, Lilly) in a cohort of pediatric patients aged 6 years to younger than 18 years with moderate to severe psoriasis."

Media quote

Topical Cannabidiol Cream and Post-exercise Recovery (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: University of New Mexico; Trial completion date: May 2022 ➔ Aug 2022; Initiation date: Oct 2021 ➔ Mar 2022; Trial primary completion date: Jan 2022 ➔ Jun 2022

Trial completion date • Trial initiation date • Trial primary completion date

Comparison of JW-100 and EUCRISA® (clinicaltrials.gov) - P3; N=184; Not yet recruiting; Sponsor: Applied Biology, Inc.; Trial completion date: Jan 2022 ➔ Apr 2022; Trial primary completion date: Dec 2021 ➔ Mar 2022

Clinical • Head-to-Head • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Topical Cannabidiol Cream and Post-exercise Recovery (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: University of New Mexico

New P1 trial

Comparison of JW-100 and EUCRISA® (clinicaltrials.gov) - P3; N=184; Not yet recruiting; Sponsor: Applied Biology, Inc.

Clinical • Head-to-Head • New P3 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial (clinicaltrials.gov) - P2/3; N=0; Withdrawn; Sponsor: Elena Pope

Clinical • New P2/3 trial • Pain

CBD Mechanism reveals potential for skin treatment (Labmate online) - "A University of Dundee study has shown for the first time why cannabidiol (CBD) is gaining momentum as a treatment for skin disorders, also pointing to its potential as a therapy for other diseases, including cancer. With known antioxidant and anti-inflammatory effects, this natural non-psychotropic cannabinoid has been tested in clinical trials for the treatment of Multiple Sclerosis, Parkinson’s and Huntington's disease and is already being used to treat seizures associated with two severe forms of epilepsy."

Clinical

Effect of Topical CBD Cream for Degenerative Hallux Disorders (clinicaltrials.gov) - P2/3; N=56; Not yet recruiting; Sponsor: Rush University Medical Center

Clinical • New P2/3 trial